<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04757597</url>
  </required_header>
  <id_info>
    <org_study_id>RIC-CAAH</org_study_id>
    <nct_id>NCT04757597</nct_id>
  </id_info>
  <brief_title>Remote Ischemic Conditioning for Cerebral Amyloid Angiopathy-related Intracerebral Hemorrhage</brief_title>
  <acronym>RIC-CAAH</acronym>
  <official_title>Safety and Efficacy of Remote Ischemic Conditioning in Patients With Cerebral Amyloid Angiopathy-related Intracerebral Hemorrhage:A Multicenter, Randomized, Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wangjing Hospital, China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bejing Fengtai You'anmen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cerebral amyloid angiopathy-related intracerebral (CAAH) hemorrhage is second factor of&#xD;
      primary intracerebral hemorrhage. However, no effective prevention and treatment strategies&#xD;
      have been established. Remote ischemic conditioning is a neuroprotective strategy. In animal&#xD;
      studies，RIC is efficiency in accelerating the absorption of hematoma. Therefore, the&#xD;
      investigators plan to carry out this research to evaluate the safety and efficacy of RIC in&#xD;
      patients with CAA related ICH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In China, primary intracerebral hemorrhage accounts for 80-85% of all types of intracerebral&#xD;
      hemorrhage, while cerebral amyloid angiopathy-related intracerebral hemorrhage is the second&#xD;
      factor, accounting for approximately 20-30%. It is often characterized by repeated and&#xD;
      multifocal lobar hemorrhage, which will not only cause neurological deficit on the limbs, but&#xD;
      also influence the cognitive level of patients and may even be life-threatening. At present,&#xD;
      the role of surgery in CAA-related ICH is controversial, and there is no effective prevention&#xD;
      and treatment strategies have been established. Additionally, it is always associated with a&#xD;
      low rate of good prognosis(11%-60%) and a high risk of recurrent ICH (10%-60%). Thus, a novel&#xD;
      approach which can improve the clinical outcome and reduce the risk of recurrent&#xD;
      intracerebral hemorrhage is urgently needed.&#xD;
&#xD;
      Remote ischemic conditioning (RIC) has been developed as a neuroprotective strategy to&#xD;
      prevent and treat acute ischemic stroke and small cerebrovascular disease. Additionally,&#xD;
      clinical research testified that RIC is safe and feasible for patients with subarachnoid&#xD;
      hemorrhage. In animal studies, RIC is efficiency in accelerating the absorption of hematoma.&#xD;
      Therefore, the investigators plan to carry out this research to evaluate the safety and&#xD;
      efficacy of RIC in patients with CAA related ICH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>90±7 days</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of intracerebral hematoma volume</measure>
    <time_frame>14± 2 days</time_frame>
    <description>Intracerebral hematoma volume (ml) is assessed by CT brain scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of perihematomal edema volume</measure>
    <time_frame>14± 2 days</time_frame>
    <description>Perihematomal edema volume (ml) is assessed by CT brain scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of the perihematomal edema expansion</measure>
    <time_frame>14± 2 days</time_frame>
    <description>The enlargement of perihematomal edema volume (ml) is assessed by CT brain scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shift of midline brain structure</measure>
    <time_frame>14± 2 days</time_frame>
    <description>Shift of midline brain structure (mm) is assessed by CT brain scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognosis of function outcome at 90 Days</measure>
    <time_frame>90±7 days</time_frame>
    <description>accessed by modified Rankin score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognosis of neurological function at 90 Days</measure>
    <time_frame>90±7 days</time_frame>
    <description>The Barthel index will be assessed at follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of serum biomarker of blood brain barrier (Matrix metalloproteinases，MMPs)</measure>
    <time_frame>7± 2 days</time_frame>
    <description>The biomarker of blood brain barrier（MMPs） are assemented by the same laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of serum biomarker of inflammatory ( interleukin)</measure>
    <time_frame>7± 2 days</time_frame>
    <description>The interleukin will be assemented by the same laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other adverse events related to RIC treatment</measure>
    <time_frame>90±7 days</time_frame>
    <description>Other adverse events related to RIC treatment,such as mucocutaneous hemorrhage,changes in coagulation function and so on.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Intracerebral Hemorrhage Lobar</condition>
  <condition>Cerebral Amyloid Angiopathy</condition>
  <arm_group>
    <arm_group_label>RIC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RIC treatment and regular treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Regular treatment alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Remote ischemic conditioning</intervention_name>
    <description>RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 10-14 days after enrollment.</description>
    <arm_group_label>RIC group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age≥55 and ≤85.&#xD;
&#xD;
          -  The diagnosis of single or multiple spontaneous lobar cerebral hemorrhage is confirmed&#xD;
             by brain CT scan(defined as possible or probable CAA by the Boston criteria) .&#xD;
&#xD;
          -  Hematoma volume of 10 to 50 ml.&#xD;
&#xD;
          -  Glasgow Coma Score (GCS)&gt;8.&#xD;
&#xD;
          -  Without surgery.&#xD;
&#xD;
          -  Starting RIC treatment between 24 and 48 hours of ictus.&#xD;
&#xD;
          -  Signed and dated informed consented is obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with suspected secondary ICH related to tumor, coagulopathy, ruptured&#xD;
             aneurysm or arteriovenous malformation, or venous sinus thrombosis.&#xD;
&#xD;
          -  ICH concomitant with intraventricular hemorrhage, subdural hematoma, epidural hematoma&#xD;
             subarachnoid hemorrhage or the condition of unstable vital signs which may be&#xD;
             life-threatening.&#xD;
&#xD;
          -  Evidence of significant shift of midline brain structure (&gt;5mm) or herniation on brain&#xD;
             imaging.&#xD;
&#xD;
          -  Contraindication to MRI scan, such as intracranial metal implants, cardiac pacemaker,&#xD;
             severe claustrophobia, history of seizures and so on&#xD;
&#xD;
          -  Patients with a pre-existing neurological deficits (modified Ranks scale score &gt;2) or&#xD;
             psychiatric disease that would confound the neurological or functional evaluations.&#xD;
&#xD;
          -  Use of warfarin or heparin within 7 days before the baseline visit&#xD;
&#xD;
          -  Contraindication for remote ischemic conditioning: severe soft tissue injury, limb&#xD;
             deformities, fracture, atrial fibrillation or peripheral vascular disease in the upper&#xD;
             limbs.&#xD;
&#xD;
          -  Life expectancy of less than 1 year due to co-morbid conditions.&#xD;
&#xD;
          -  Severe, sustained hypertension (SBP &gt; 180 mmHg or DBP &gt; 110 mmHg).&#xD;
&#xD;
          -  Severe hepatic and renal dysfunction.&#xD;
&#xD;
          -  Known pregnancy (or positive pregnancy test), or breast-feeding.&#xD;
&#xD;
          -  Concurrent participation in another research protocol for investigation of another&#xD;
             experimental therapy.&#xD;
&#xD;
          -  Any condition which, in the judgment of the investigator, might increase the risk to&#xD;
             the patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xunming Ji</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuanwu Hospital, Beijing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xunming Ji, MD PhD</last_name>
    <phone>010-83199430</phone>
    <email>jixm@ccmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruiwen Che, MD</last_name>
    <email>rwcadl@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xuan Wu Hospital，Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xunming ji</last_name>
      <phone>861013120136877</phone>
      <email>jixunming@vip.163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Yamada M. Cerebral amyloid angiopathy: emerging concepts. J Stroke. 2015 Jan;17(1):17-30. doi: 10.5853/jos.2015.17.1.17. Epub 2015 Jan 30. Review.</citation>
    <PMID>25692104</PMID>
  </reference>
  <reference>
    <citation>Arima H, Tzourio C, Anderson C, Woodward M, Bousser MG, MacMahon S, Neal B, Chalmers J; PROGRESS Collaborative Group. Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke. 2010 Feb;41(2):394-6. doi: 10.1161/STROKEAHA.109.563932. Epub 2009 Dec 31.</citation>
    <PMID>20044530</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 13, 2021</study_first_submitted>
  <study_first_submitted_qc>February 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>June 13, 2021</last_update_submitted>
  <last_update_submitted_qc>June 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Ji Xunming,MD,PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Cerebral Amyloid Angiopathy</mesh_term>
    <mesh_term>Cerebral Amyloid Angiopathy, Familial</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

